Interestingly, the expansion of CD56− NK cells was associated with a higher rate of DMR, and Wei et al. also reported that dasatinib increased the percentage of Th1 and CD8 T cells and decreased Treg cell levels in the peripheral blood of CML patients who responded to therapy [44]. This evidence concerns the gene NCAM1 and chronic myelogenous leukemia, BCR-ABL1 positive.